Cargando…

Dihydroergotamine inhibits the vasodepressor sensory CGRPergic outflow by prejunctional activation of α(2)-adrenoceptors and 5-HT(1) receptors

BACKGROUND: Dihydroergotamine (DHE) is an antimigraine drug that produces cranial vasoconstriction and inhibits trigeminal CGRP release; furthermore, it inhibits the vasodepressor sensory CGRPergic outflow, but the receptors involved remain unknown. Prejunctional activation of α(2A/2C)-adrenergic, s...

Descripción completa

Detalles Bibliográficos
Autores principales: González-Hernández, Abimael, Lozano-Cuenca, Jair, Marichal-Cancino, Bruno A., MaassenVanDenBrink, Antoinette, Villalón, Carlos M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5970131/
https://www.ncbi.nlm.nih.gov/pubmed/29802544
http://dx.doi.org/10.1186/s10194-018-0869-8
_version_ 1783326058853957632
author González-Hernández, Abimael
Lozano-Cuenca, Jair
Marichal-Cancino, Bruno A.
MaassenVanDenBrink, Antoinette
Villalón, Carlos M.
author_facet González-Hernández, Abimael
Lozano-Cuenca, Jair
Marichal-Cancino, Bruno A.
MaassenVanDenBrink, Antoinette
Villalón, Carlos M.
author_sort González-Hernández, Abimael
collection PubMed
description BACKGROUND: Dihydroergotamine (DHE) is an antimigraine drug that produces cranial vasoconstriction and inhibits trigeminal CGRP release; furthermore, it inhibits the vasodepressor sensory CGRPergic outflow, but the receptors involved remain unknown. Prejunctional activation of α(2A/2C)-adrenergic, serotonin 5-HT(1B/1F), or dopamine D(2)-like receptors results in inhibition of this CGRPergic outflow. Since DHE displays affinity for these receptors, this study investigated the pharmacological profile of DHE-induced inhibition of the vasodepressor sensory CGRPergic outflow. METHODS: Pithed rats were pretreated i.v. with hexamethonium (2 mg/kg·min) followed by continuous infusions of methoxamine (20 μg/kg·min) and DHE (3.1 μg/kg·min). Then, stimulus-response curves (spinal electrical stimulation; T(9)-T(12)) or dose-response curves (i.v. injections of α-CGRP) resulted in frequency-dependent or dose-dependent decreases in diastolic blood pressure. RESULTS: DHE inhibited the vasodepressor responses to electrical stimulation (0.56–5.6 Hz), without affecting those to i.v. α-CGRP (0.1–1 μg/kg). This inhibition by DHE (not produced by the methoxamine infusions): (i) was abolished by pretreatment with the combination of the antagonists rauwolscine (α(2)-adrenoceptor; 310 μg/kg) plus GR127935 (5-HT(1B/1D); 31 μg/kg); and (ii) remained unaffected after rauwolscine (310 μg/kg), GR127935 (31 μg/kg) or haloperidol (D(2)-like; 310 μg/kg) given alone, or after the combination of rauwolscine plus haloperidol or GR127935 plus haloperidol at the aforementioned doses. CONCLUSION: DHE-induced inhibition of the vasodepressor sensory CGRPergic outflow is mainly mediated by prejunctional rauwolscine-sensitive α(2)-adrenoceptors and GR127935-sensitive 5-HT(1B/1D) receptors, which correlate with α(2A/2C)-adrenoceptors and 5-HT(1B) receptors, respectively. These findings suggest that DHE-induced inhibition of the perivascular sensory CGRPergic outflow may facilitate DHE’s vasoconstrictor properties resulting in an increased vascular resistance. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s10194-018-0869-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5970131
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer Milan
record_format MEDLINE/PubMed
spelling pubmed-59701312018-06-11 Dihydroergotamine inhibits the vasodepressor sensory CGRPergic outflow by prejunctional activation of α(2)-adrenoceptors and 5-HT(1) receptors González-Hernández, Abimael Lozano-Cuenca, Jair Marichal-Cancino, Bruno A. MaassenVanDenBrink, Antoinette Villalón, Carlos M. J Headache Pain Research Article BACKGROUND: Dihydroergotamine (DHE) is an antimigraine drug that produces cranial vasoconstriction and inhibits trigeminal CGRP release; furthermore, it inhibits the vasodepressor sensory CGRPergic outflow, but the receptors involved remain unknown. Prejunctional activation of α(2A/2C)-adrenergic, serotonin 5-HT(1B/1F), or dopamine D(2)-like receptors results in inhibition of this CGRPergic outflow. Since DHE displays affinity for these receptors, this study investigated the pharmacological profile of DHE-induced inhibition of the vasodepressor sensory CGRPergic outflow. METHODS: Pithed rats were pretreated i.v. with hexamethonium (2 mg/kg·min) followed by continuous infusions of methoxamine (20 μg/kg·min) and DHE (3.1 μg/kg·min). Then, stimulus-response curves (spinal electrical stimulation; T(9)-T(12)) or dose-response curves (i.v. injections of α-CGRP) resulted in frequency-dependent or dose-dependent decreases in diastolic blood pressure. RESULTS: DHE inhibited the vasodepressor responses to electrical stimulation (0.56–5.6 Hz), without affecting those to i.v. α-CGRP (0.1–1 μg/kg). This inhibition by DHE (not produced by the methoxamine infusions): (i) was abolished by pretreatment with the combination of the antagonists rauwolscine (α(2)-adrenoceptor; 310 μg/kg) plus GR127935 (5-HT(1B/1D); 31 μg/kg); and (ii) remained unaffected after rauwolscine (310 μg/kg), GR127935 (31 μg/kg) or haloperidol (D(2)-like; 310 μg/kg) given alone, or after the combination of rauwolscine plus haloperidol or GR127935 plus haloperidol at the aforementioned doses. CONCLUSION: DHE-induced inhibition of the vasodepressor sensory CGRPergic outflow is mainly mediated by prejunctional rauwolscine-sensitive α(2)-adrenoceptors and GR127935-sensitive 5-HT(1B/1D) receptors, which correlate with α(2A/2C)-adrenoceptors and 5-HT(1B) receptors, respectively. These findings suggest that DHE-induced inhibition of the perivascular sensory CGRPergic outflow may facilitate DHE’s vasoconstrictor properties resulting in an increased vascular resistance. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s10194-018-0869-8) contains supplementary material, which is available to authorized users. Springer Milan 2018-05-25 /pmc/articles/PMC5970131/ /pubmed/29802544 http://dx.doi.org/10.1186/s10194-018-0869-8 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Research Article
González-Hernández, Abimael
Lozano-Cuenca, Jair
Marichal-Cancino, Bruno A.
MaassenVanDenBrink, Antoinette
Villalón, Carlos M.
Dihydroergotamine inhibits the vasodepressor sensory CGRPergic outflow by prejunctional activation of α(2)-adrenoceptors and 5-HT(1) receptors
title Dihydroergotamine inhibits the vasodepressor sensory CGRPergic outflow by prejunctional activation of α(2)-adrenoceptors and 5-HT(1) receptors
title_full Dihydroergotamine inhibits the vasodepressor sensory CGRPergic outflow by prejunctional activation of α(2)-adrenoceptors and 5-HT(1) receptors
title_fullStr Dihydroergotamine inhibits the vasodepressor sensory CGRPergic outflow by prejunctional activation of α(2)-adrenoceptors and 5-HT(1) receptors
title_full_unstemmed Dihydroergotamine inhibits the vasodepressor sensory CGRPergic outflow by prejunctional activation of α(2)-adrenoceptors and 5-HT(1) receptors
title_short Dihydroergotamine inhibits the vasodepressor sensory CGRPergic outflow by prejunctional activation of α(2)-adrenoceptors and 5-HT(1) receptors
title_sort dihydroergotamine inhibits the vasodepressor sensory cgrpergic outflow by prejunctional activation of α(2)-adrenoceptors and 5-ht(1) receptors
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5970131/
https://www.ncbi.nlm.nih.gov/pubmed/29802544
http://dx.doi.org/10.1186/s10194-018-0869-8
work_keys_str_mv AT gonzalezhernandezabimael dihydroergotamineinhibitsthevasodepressorsensorycgrpergicoutflowbyprejunctionalactivationofa2adrenoceptorsand5ht1receptors
AT lozanocuencajair dihydroergotamineinhibitsthevasodepressorsensorycgrpergicoutflowbyprejunctionalactivationofa2adrenoceptorsand5ht1receptors
AT marichalcancinobrunoa dihydroergotamineinhibitsthevasodepressorsensorycgrpergicoutflowbyprejunctionalactivationofa2adrenoceptorsand5ht1receptors
AT maassenvandenbrinkantoinette dihydroergotamineinhibitsthevasodepressorsensorycgrpergicoutflowbyprejunctionalactivationofa2adrenoceptorsand5ht1receptors
AT villaloncarlosm dihydroergotamineinhibitsthevasodepressorsensorycgrpergicoutflowbyprejunctionalactivationofa2adrenoceptorsand5ht1receptors